Development of Antibodies to Angiogenic Factors for Diagnosis and Therapy of Solid Tumors.
Development of Antibodies to Angiogenic Factors for Diagnosis and Therapy of Solid Tumors.
批准号:
09557129
负责人:
KATO Tetsuro
金额:
$7.87万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999
中文摘要
The relationship between tumor angiogenesis and angiogenic factors was evaluated in renal cell carcinoma(RCC)and urinary bladder carcinoma(BC Ii D2a Iee D2)。VEGF genes,VEGFⅡD2121ⅡD2 and VEGFⅡD2165ⅡD2,were overexpressed in 60%of RCCs。The Expression level of VEGF genes was significantly correlated with the intratumoral microvessel density.An immunohistologic analysis was done with and anti-VEGF antiserum that had been raised by immunizing a rabbit with an oligopeptide homologous to the N-terminal of VEGF。Cytoplasm of RCC appeared to be positive to the VEGF staining.VEGF genes were also overexpressed in 40%of Bcas.At protein level,VEGF was apparently positive in bladder carcinoma cells.VEGF-receptor genes were expressed in concordance with the VEGF gene expression level in both tumors.Thus,angiogenesis in RCC and Bca is suggested to be facilitated by a paracrine mechanism with VEGF and its receptors.VEGF-relating genes(VEGF-A,B,C,and D)and their receptor genes have been…More cloned one after another.We studies the expression of these genes in RCCs and found that VEGF-A and the receptors,VEGFR-1and VEGFR-2,play crucial roles in the angiogenesis of RCC while VEGF-B and VEGF-C do little.Based on the above results,we compared serum VEGF levels between a RCC patient group and a healthy control group.The mean serum VEGF level was higher in the RCC patient group than in the healthy control group.Postoperative serum VEGF level apparently decreased as compared with the preoperative level.Serum VEGF level was significantly correlated with tumor volume,metastasis,and stage.When the VEGF cut-off value was set at 100pg/ml based on a receiver-operator curve analysis,the sensitivity and the specificity of RCC were 80.0%and 72.5%,respectively.Thus we suggest that RCC releases VEGF into the blood circulation and serum VEGF level would be a marker of malignant potential of RC.Taken together,these results would be useful as basic data for the development of anti-angiogenic-factor antibody facilitating diagnosis and therapy of RCC。Less:Less
英文摘要
The relationship between tumor angiogenesis and angiogenic factors was evaluated in renal cell carcinoma (RCC) and urinary bladder carcinoma (BCィイD2aィエD2). VEGF genes, VEGFィイD2121ィエD2 and VEGFィイD2165ィエD2, were overexpressed in 60% of RCCs. The Expression level of VEGF genes was significantly correlated with the intratumoral microvessel density. An immunohistologic analysis was done with and anti-VEGF antiserum that had been raised by immunizing a rabbit with an oligopeptide homologous to the N-terminal of VEGF. Cytoplasm of RCC appeared to be positive to the VEGF staining. VEGF genes were also overexpressed in 40% of Bcas. At protein level, VEGF was apparently positive in bladder carcinoma cells. VEGF-receptor genes were expressed in concordance with the VEGF gene expression level in both tumors. Thus, angiogenesis in RCC and Bca is suggested to be facilitated by a paracrine mechanism with VEGF and its receptors.VEGF-relating genes (VEGF-A,B,C, and D) and their receptor genes have been … More cloned one after another. We studies the expression of these genes in RCCs and found that VEGF-A and the receptors, VEGFR-1 and VEGFR-2, play crucial roles in the angiogenesis of RCC while VEGF-B and VEGF-C do little.Based on the above results, we compared serum VEGF levels between a RCC patient group and a healthy control group. The mean serum VEGF level was higher in the RCC patient group than in the healthy control group. Postoperative serum VEGF level apparently decreased as compared with the preoperative level. Serum VEGF level was significantly correlated with tumor volume, metastasis, and stage. When the VEGF cut-off value was set at 100pg/ml based on a receiver-operator curve analysis, the sensitivity and the specificity of RCC were 80.0% and 72.5%, respectively. Thus we suggest that RCC releases VEGF into the blood circulation and serum VEGF level would be a marker of malignant potential of RCC.Taken together, these results would be useful as basic data for the development of anti-angiogenic-factor antibody facilitating diagnosis and therapy of RCC. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
佐藤一成、 加藤哲郎: "腎細胞癌における腫瘍血管の増生と血管増生因子の相関" 癌と化学療法. 24. 389-39 (1997)
Kazunari Sato、Tetsuro Kato:“肾细胞癌中肿瘤血管增殖与血管生长因子的相关性”《癌症与化疗》24. 389-39 (1997)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kazunari Sato et al.: "Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma."Jpn J Cancer Res. 90. 874-879 (1999)
Kazunari Sato 等人:“肾细胞癌患者血管内皮生长因子的血清水平升高。”Jpn J Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sato K et al.: "Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma."Jpn J Cancer Res. 90. 874-9 (1999)
Sato K 等人:“肾细胞癌患者血管内皮生长因子的血清水平升高。”Jpn J Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
佐藤一成、加藤哲郎: "腎細胞癌における腫瘍血管の増生と血管増生因子の相関"癌と化学療法. 24. 389-394 (1997)
Kazunari Sato、Tetsuro Kato:“肾细胞癌中肿瘤血管增殖与血管生长因子的相关性”《癌症与化疗》24. 389-394 (1997)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Norihiko Tsuchiya, et al.: "Quantitative analysis of VEGF,VEGF-C and VEGFR-2 gene expression in renal cell carcinoma"J Urol. 161. 143A (1999)
Norihiko Tsuchiya 等:“肾细胞癌中 VEGF、VEGF-C 和 VEGFR-2 基因表达的定量分析”J Urol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
War of Information on the Siberian internment returnees between USA and USSR
-
批准号:26380188
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2014
-
负责人:KATO Tetsuro
-
依托单位:
The War of Information about a member of the wartime Japanese Embassy in Germany: Shigeki Sakimura and his Desertion
-
批准号:23530170
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.24万
-
财政年份:2011
-
负责人:KATO Tetsuro
-
依托单位:
Politics of Mobility and Information Network : The "Empire" and the Crossing Border by "Multitude"
-
批准号:19330031
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.48万
-
财政年份:2007
-
负责人:KATO Tetsuro
-
依托单位:
Informational Community of Japanese Intellectuals Abroad during Two World Wars
-
批准号:15530087
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:2003
-
负责人:KATO Tetsuro
-
依托单位:
RESEARCH BY INTERNET ON THE JAPANESE ANTI-NAZIS INTELLECTUALS IN BERLIN : FROM WEIMAR GERMAN TO POST-WAR JAPANESE DEMOCRACY
-
批准号:10620063
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:KATO Tetsuro
-
依托单位:
Dynamics and Biological Significance of Vascular Growth Factors in Urogenital Cancers.
-
批准号:10470330
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$8.32万
-
财政年份:1998
-
负责人:KATO Tetsuro
-
依托单位:
Pathological and biological analyzes of angiogenesis on urological cancers
-
批准号:08457419
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$1.09万
-
财政年份:1996
-
负责人:KATO Tetsuro
-
依托单位:
The Scale and Mechanism of Japanese Victims of Stalinist Terror in the USSR in the 1930s
-
批准号:07620055
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1995
-
负责人:KATO Tetsuro
-
依托单位:
Significance of c-erbB-2 and its ligand affecting malignant potential of urological carcinomas.
-
批准号:05454430
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.03万
-
财政年份:1993
-
负责人:KATO Tetsuro
-
依托单位:
Development of Novel Anticancer Drug-Carriers Targetable to Tumor Blood Vessels.
-
批准号:04557072
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B)
-
资助金额:$9.92万
-
财政年份:1992
-
负责人:KATO Tetsuro
-
依托单位:
Analysis of Histopathological Heterogeneity of Urinary Bladder Cancer by Molecular Biological Technique.
-
批准号:63480357
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.03万
-
财政年份:1988
-
负责人:KATO Tetsuro
-
依托单位:
Nuclear Magnetic Resonance Analysis in Urological Disorders.
-
批准号:59480324
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.9万
-
财政年份:1984
-
负责人:KATO Tetsuro
-
依托单位:
Synthesis of New Hematoporphyrin Derivatives Providing a Tumor-Specificity
-
批准号:59870053
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$4.29万
-
财政年份:1984
-
负责人:KATO Tetsuro
-
依托单位:
海外基金